Speaker illustration

Doctor Masa-Aki Kawashiri

Kanazawa University Graduate School of Medicine, Kanazawa (Japan)

Member of:

European Society of Cardiology

Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular ldl-apheresis therapy in patients with heterozygous familial hypercholesterolemia.

Event: ESC Congress 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Lipids

Thumbnail

ESC 365 is supported by